Project Grant HT94252410970
Award Date
11/1/24
Completion Date
10/31/26
Dollars Obligated
$188K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
The U.S. Defense Health Agency awarded a $700,788 Project Grant to The Institute For Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project to study the targeting of the nuclear necroptosis pathway in the pancreatic cancer microenvironment. As a prime grantee, The Institute For Cancer Research will conduct preclinical testing, biomarker analysis, and other specialized...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,128,000 Project Grant to The Institute For Cancer Research to conduct research on "Restoring PALB2 Function as a Mechanism of PARP1 Resistance in BRCA1-Mutant EOC". The award, with a performance period from July 1, 2024 to June 30, 2028, supports innovative scientific research aimed at improving health outcomes for military service members, veterans, and the broader...
The Institute For Cancer Research, a non-profit research organization and subsidiary of Temple University, was awarded a $534,445 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate NETRIN G1 ligand as a new immunomodulatory target and early biomarker in pancreatic cancer, with a project period from August 1, 2023 to July 31, 2026. The Institute For Cancer Research has extensive...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
This Project Grant award in the amount of $679,085.00 was issued by the Defense Health Agency, a component of the Department of Defense, under the Military Medical Research and Development program (CFDA 12.420). The funding supports research by Temple University-Of The Commonwealth System Of Higher Education, through its division Temple University, to investigate the role of tumor-associated sensory neurons in breast cancer invasion and metastasis. The award period runs from January 15, 2024...
This Project Grant award from the Department of Defense's Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $564,000.00 to The Institute For Cancer Research, a subsidiary of Temple University, to increase clinical trial enrollment of underrepresented kidney cancer patients by improving access to participation. The award is for a two-year period from September 1, 2023 to August 31, 2025. The Institute For Cancer Research will leverage its...
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
The federal Project Grant award for "TARGETING P2X7 RECEPTOR IN RENAL CELL CARCINOMA", totaling $1,269,000.00, was awarded to The Institute For Cancer Research, a non-profit subsidiary of Temple University, by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports biomedical research focused on developing new treatments for kidney cancer, a key health concern for military service members and veterans. The Institute For...